Amylyx Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMLX and other ETFs, options, and stocks.About AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada.
CEOJoshua B. Cohen
CEOJoshua B. Cohen
Employees123
Employees123
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2013
Founded2013
Employees123
Employees123
AMLX Key Statistics
Market cap1.47B
Market cap1.47B
Price-Earnings ratio-5.50
Price-Earnings ratio-5.50
Dividend yield—
Dividend yield—
Average volume1.24M
Average volume1.24M
High today$13.88
High today$13.88
Low today$13.11
Low today$13.11
Open price$13.16
Open price$13.16
Volume909.61K
Volume909.61K
52 Week high$16.96
52 Week high$16.96
52 Week low$2.60
52 Week low$2.60
Stock Snapshot
As of today, Amylyx Pharmaceuticals(AMLX) shares are valued at $13.74. The company's market cap stands at 1.47B, with a P/E ratio of -5.50.
On 2025-11-05, Amylyx Pharmaceuticals(AMLX) stock traded between a low of $13.11 and a high of $13.88. Shares are currently priced at $13.74, which is +4.8% above the low and -1.0% below the high.
Amylyx Pharmaceuticals(AMLX) shares are trading with a volume of 909.61K, against a daily average of 1.24M.
During the past year, Amylyx Pharmaceuticals(AMLX) stock moved between $2.60 at its lowest and $16.96 at its peak.
During the past year, Amylyx Pharmaceuticals(AMLX) stock moved between $2.60 at its lowest and $16.96 at its peak.
Analyst ratings
100%
of 10 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own AMLX. This list is generated using Robinhood data, and it’s not a recommendation.